Live Breaking News & Updates on நோவர்த்திச் நரசிம்மன்
Stay updated with breaking news from நோவர்த்திச் நரசிம்மன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis in Talks to Join Pharma Industry’s Covid Vaccine Push Bloomberg 1/28/2021 Naomi Kresge and Francine Lacqua (Bloomberg) Novartis AG is in talks to help produce other companies’ coronavirus vaccines or treatments as the industry mobilizes to boost supply amid fights over access. Popular Searches The company is “in conversations with a range of different players,” Chief Executive Officer Vas Narasimhan said on Bloomberg TV, with an agreement possible in the coming days or weeks. “We have production capacity across our network that we’re willing to make available,” he said, for everything from monoclonal antibodies to vaccine production. ....
Message : Required fields (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan s move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma s Chinese M&A dreams. Novartis will co-develop BeiGene s tislelizumab, an anti-PD-1 antibody similar to Keytruda from Merck and Opdivo from Bristol-Myers Squibb which help the immune system attack cancer and which have reaped billions of dollars in sales. ....
Novartis’s China foray follows Pfizer deal in September Swiss drugmaker playing catch-up on cancer immunotherapy Novartis CEO was previously tepid on Chinese assets Jan 12 (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd , the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan’s move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma’s Chinese M&A dreams. ....